Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED

Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >

What This Label Expansion Means for Merck ↗

August 22, 2021

The Keytruda-Lenvima combo was recently approved for its second oncology indication.

Via The Motley Fool

White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg ↗

August 20, 2021

The Biden Administration has ruled out the nomination of acting FDA commissioner Janet Woodcock as permanent head of the agency, Bloomberg reported citing people...

Via Benzinga

Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's ↗

August 17, 2021

Eisai Co Ltd (OTC: ESALY) and its U.S. partner Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm (aducanumab) will be used by more than 300...

Via Benzinga

The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow ↗

August 15, 2021

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among...

Via Talk Markets

Topics Initial Public Offering

The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow ↗

August 15, 2021

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-...

Via Benzinga

Topics Initial Public Offering

Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs ↗

August 12, 2021

The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC:...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates ↗

August 02, 2021

The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi...

Via Benzinga

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

News Overload ↗

July 29, 2021

Today US markets managed a rally despite misses in both the growth and employment data.

Via Talk Markets

Full News Day ↗

July 28, 2021

The US greatly increased its exports of liquified natural gas in the first half-year, to 9.6 billion cubic feet per day, a rise of 42% from a year earlier.

Via Talk Markets

Topics Energy

Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients ↗

July 27, 2021

An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) ...

Via Benzinga

Containment Plan ↗

July 23, 2021

Today the US decided to cut China risks.

Via Talk Markets

Joblessness Surprise ↗

July 22, 2021

Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices.

Via Talk Markets

The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO ↗

July 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical...

Via Benzinga

“Claw-Back” day ↗

July 20, 2021

The rally was just as irrational as the selloff.

Via Talk Markets

Delta Defeats Bulls ↗

July 19, 2021

Stocks tended to crash without rhyme or reason.

Via Talk Markets

Weak Week ↗

July 16, 2021

Friday tried a recovery because retail sales data for June were strong, particularly in dining out, although in the end, the weak tech side cut the optimism.

Via Talk Markets

Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News ↗

July 15, 2021

Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency's controversial approval of Alzheimer's treatment, Aduhelm developed by ...

Via Benzinga

Dialing For Stocks ↗

July 14, 2021

Thanks to Fed Chairman Powell, markets brushed off worrying about inflation today.

Via Talk Markets

Topics Economy

FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients ↗

July 08, 2021

Biogen Inc. (NASDAQ:BIIB) shares are lower after the compa...

Via Benzinga

People Needed ↗

July 02, 2021

If qualified people are not looking for work, they will have to be lured to do so with higher wages.

Via Talk Markets

End Of June ↗

June 30, 2021

Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made.

Via Talk Markets

Topics Initial Public Offering

Summer Friday ↗

June 25, 2021

The stock market tried for another record after yesterday's late blowout over the infrastructure deal.

Via Talk Markets

Crazy Thursday ↗

June 24, 2021

Today the US stock market went ballistic probably because of a higher joblessness level than expected.

Via Talk Markets

Wednesday Is A Normal Day ↗

June 23, 2021

Meme stocks Gamestop and Torchlight Energy both did share sales to cash in on their share price rises.

Via Talk Markets

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗

June 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

The First Day Of Summer And Prime Day ↗

June 21, 2021

The bull is back in business today.

Via Talk Markets

3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations ↗

June 20, 2021

Beyond its lofty price tag, there are other impediments to big sales of aducanamab that the market largely ignored this week.

Via The Motley Fool

Did This Company Just Win Big Because of Biogen? ↗

June 20, 2021

Alzheimer's disease patients who take Aduhelm will need a lot of diagnostic scans, too. Imaging leader RadNet stands to benefit.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.